论文部分内容阅读
目的评价SPECT/CT断层融合显像在分化型甲状腺癌131I治疗后的应用价值。方法分化型甲状腺癌(DTC)术后患者49例,于131I治疗后5~7d行SPECT/CT全身平面显像(WBS)和局部断层融合显像,诊断结果与病理或其他影像检查及临床随访结果对比,分析其灵敏度及准确率。结果平面显像发现异常摄碘疑诊为转移灶40处,灵敏度、准确率分别为76.09%(35/46)、68.63%(35/51);断层显像发现异常摄碘诊断为转移灶45处,灵敏度、准确率分别为93.48%(43/46)、89.58%(43/48)。结论 DTC患者131I治疗后,SPECT/CT断层融合显像诊断转移灶的效能明显优于平面显像,SPECT/CT断层融合显像对DTC术后转移的诊断有较高的应用价值。
Objective To evaluate the value of SPECT / CT fusion imaging in the treatment of differentiated thyroid carcinoma 131I. Methods Forty-nine patients with differentiated thyroid cancer (DTC) underwent postoperative radiotherapy with SPECT / CT whole body fusion imaging (FECT) and local fusion imaging (FECT) 5 to 7 days after 131I treatment. The diagnostic results were compared with pathological or other imaging and clinical follow-up The results of contrast, analysis of its sensitivity and accuracy. Results The abnormalities of iodine and iodine were detected in 40 sites of metastases by plain imaging. The sensitivity and accuracy were 76.09% (35/46) and 68.63% (35/51) respectively. The imaging findings of abnormal iodine were diagnosed as metastasis Department, sensitivity, accuracy were 93.48% (43/46), 89.58% (43/48). Conclusions After 131I treatment of DTC patients, SPECT / CT fusion imaging is more effective than plain imaging in the diagnosis of metastatic lesions. SPECT / CT fusion imaging has high value in the diagnosis of DTC metastasis.